Secondary hyperparathyroidism (SHPT) is a common complication of chronic kidney disease (CKD), for which there are unmet needs surrounding its management. Four posters presented at international congresses in 2019 and 2020 investigated the management of SHPT, including the efficacy and safety of current and future treatments.
EMJ Nephrology 8 [Supplement 3] . 2020
Latest articlesAll articles
Ocedurenone: A Novel Therapy for Uncontrolled Hypertension in Advanced Chronic Kidney Disease
Setting the scene, Bakris defined CKD as a reduction in kidney function (estimated glomerular filtration rate [eGFR] <60 mL/min/1.73 m2), alongside the presence of albuminuria (≥30 mg/day) as an indication of kidney damage.
Editor's Pick: Metabolic Acidosis in Children: A Literature Review
Metabolic acidosis is characterised by a primary decrease in the serum bicarbonate concentration, a secondary decrease in the arterial partial pressure of CO2, and a reduction in blood pH. Metabolic acidosis, acute or chronic, may have deleterious effects on cellular function and cause increased morbidity and mortality.
Hypertension in Patients Receiving Dialysis: A Review of the Current Clinical Approach
Hypertension is a common complication in advanced chronic kidney disease (CKD), occurring in approximately 80–85% of patients. Blood pressure (BP) control is suboptimal in the majority of these patients. The link between uncontrolled hypertension and mortality among patients with end-stage kidney disease (ESKD) is well documented.
Prevalence of SARS-CoV-2 Cellular and Humoral Immunity Amongst Patients on Dialysis After the First Vaccination Campaign
Global immunisation against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the standard-of-care in preventing COVID-19 and, in the absence of a specific antiviral therapy, the only effective action against this pandemic.